U.S. Markets closed
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,768.40
    -9.80 (-0.55%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1696
    -0.0034 (-0.2924%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • USD/JPY

    109.7800
    +0.5600 (+0.5127%)
     
  • BTC-USD

    44,618.79
    +1,252.41 (+2.89%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Kintara Stock Soars After Site Activation Update On Glioblastoma Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Kintara Therapeutics Inc (NASDAQ: KTRA) has announced that the VAL-083 treatment arm in the Global Coalition for Adaptive Research registrational Phase 2/3 trial for glioblastoma multiforme (GBM) has been activated.

  • The trial, titled GBM AGILE, is a patient-centered, adaptive platform trial for registration evaluating multiple therapies for newly diagnosed and recurrent GBM.

  • The trial plans to enroll 150-200 patients in the Kintara arm of the study at 30 sites in the U.S. and Canada, potentially increasing this total to 40 clinical trial centers.

  • In GBM AGILE, VAL-083 is the only therapeutic agent currently being evaluated in all three GBM patient subtypes.

  • It may accelerate VAL-083's time to pivotal trial completion and potential regulatory submission by up to 18 months.

  • It provides a cost-effective opportunity to advance VAL-083 due to the GBM AGILE study's expense-sharing protocol.

  • Kintara's VAL-083 is a "first-in-class," small-molecule bifunctional alkylating agent that crosses the blood-brain barrier.

  • Price Action: KTRA shares are 13.5% at $1.68 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.